3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Melanoma
9
Urinary Bladder Neoplasms
2
Stomach Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Neoplasms
2
Esophageal Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Transitional Cell
2
Carcinoma, Renal Cell
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma, Hepatocellular
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Turcot syndrome
1
Thyroid Neoplasms
1
Tertiary Lymphoid Structures
1
Sarcoma
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Neoplasm Metastasis
1
Nasopharyngeal Carcinoma
1
Muscle Invasive Bladder Urothelial Carcinoma
1
Multiple Myeloma
1
Microsatellite Instability
1
Melanoma, Cutaneous Malignant
1
Interventions
Doxorubicin
13
Specimen Handling
12
pembrolizumab
11
Magnetic Resonance Spectroscopy
10
Biopsy
10
Cyclophosphamide
9
X-Rays
7
Ifosfamide
7
Radiotherapy
6
Phantoms, Imaging
6
Gemcitabine
6
liposomal doxorubicin
5
Nivolumab
5
tazemetostat
4
palbociclib
4
fludarabine
4
atezolizumab
4
Temozolomide
4
Radiation
4
Nuclear Medicine Department, Hospital
4
Irinotecan
4
larotrectinib
3
cabozantinib
3
Surveys and Questionnaires
3
Ipilimumab
3
Carboplatin
3
Bevacizumab
3
ulixertinib
2
tipifarnib
2
selpercatinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Sarcoma
×
relatlimab
×
90 days
×
Clear all
NCT04095208
2026-04-21
CONGRATS
Institut Bergonié
Phase 2
Completed
68 enrolled